Design, Preparation and Studies Regarding Cytotoxic Properties of Glycyrrhetinic Acid Derivatives

Biol Pharm Bull. 2020;43(1):102-109. doi: 10.1248/bpb.b19-00615.

Abstract

Glycyrrhetinic acid (GA) is a natural product with certain antitumor activity. In order to enhance the cytotoxicity, a total of eighteen derivatives of GA were designed and synthesized. Their cytotoxicity against MDA-MB-231cells (human breast cancer cells) and HeLa cells (human cervical cancer cells), were evaluated by the MTT method (3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide). The results indicated that these target compounds have a wide molar activity range and some of them show better activity than the commercial drugs gefitinib and doxorubicin. Compound 6g induces apoptosis of 7, 10 and 44% of MDA-MB-231 cells at 5, 10, and 20 µM, respectively.

Keywords: MDA-MB-231; apoptosis; cytotoxicity; glycyrrhetinic acid.

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Doxorubicin / pharmacology
  • Gefitinib / pharmacology
  • Glycyrrhetinic Acid / analogs & derivatives*
  • Glycyrrhetinic Acid / chemistry
  • Glycyrrhetinic Acid / pharmacology*
  • Humans
  • Structure-Activity Relationship

Substances

  • Antineoplastic Agents
  • Doxorubicin
  • Glycyrrhetinic Acid
  • Gefitinib